Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 13/20 | 0.47 |
| ▸ | SLC6A3 known ✓ | Q01959 | 12/20 | 0.47 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.35 |
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 0.35 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.35 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 11/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 11/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 11/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.47 |
| ▸ | CHRNA1 | P02708 | 10/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 10/20 | 0.40 |
| ▸ | CHRNG | P07510 | 9/20 | 0.40 |
| ▸ | CHRND | Q07001 | 9/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL2599546 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL2599510 | 0.90 | SLC6A2 (0.55) | SLC6A2SLC6A3CHRNB2CHRNB4CHRNA3 | |
| Fumaric Acid SCHEMBL2599574 | 0.86 | SLC6A2 (0.52) | SLC6A2SLC6A3CHRNB2CHRNB4CHRNA3 | |
| Fumaric Acid SCHEMBL2599572 | 0.86 | SLC6A2 (0.52) | SLC6A2SLC6A3CHRNB2CHRNB4CHRNA3 | |
| Fumaric Acid SCHEMBL2599506 | 0.86 | CHRNB2 (0.52) | SLC6A2SLC6A3CHRNB2CHRNB4CHRNA3 | |
| Fumaric Acid SCHEMBL2599504 | 0.86 | CHRNB2 (0.52) | SLC6A2SLC6A3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL2599498 | 0.75 | CHRNB2 (0.59) | SLC6A2SLC6A3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL5385861 | 0.75 | SLC6A2 (0.40) | SLC6A2SLC6A3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL12186459 | 0.75 | CHRNB2 (0.59) | SLC6A2SLC6A3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL2599547 | 0.75 | L3MBTL1 (0.36) | SLC6A2SLC6A3CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571858-B1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | RES TRIANGLE INST (US) | 2018-06-20 | — | — | EP | disclosed |
| US-9617229-B2 | Phenylmorpholines and analogues thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2017-04-11 | — | — | US | disclosed |
| US-20130203752-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | NIH-DEITR | 2013-08-08 | — | — | US | disclosed |
| EP-2571858-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | Research Triangle Institute (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011146850-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203752-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | PNMT, OPRL1, OPRM1 | SLC6A2 5/4885SLC6A3 8/4885DRD2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.